Spinal muscular atrophy is a genetic disorder characterized by progressive muscle weakness, severely impacting patients' motor abilities. Several disease modifying therapies have been developed to treat Spinal muscular atrophy which have led to new disease trajectories . According to standard of care guidelines, exercise programs should be designed and monitored by a physical therapist and should …
Spinal muscular atrophy is a genetic disorder characterized by progressive muscle weakness, severely impacting patients' motor abilities. Several disease modifying therapies have been developed to treat Spinal muscular atrophy which have led to new disease trajectories . According to standard of care guidelines, exercise programs should be designed and monitored by a physical therapist and should include exercises to improve daily life activities. Exercises should be adapted to each patient and can be prescribed with an optimal frequency in various ways. However, of patients with Spinal muscular atrophy, only 20% reported access to endurance exercises and only 6% to mixed exercises. This incompliance to standard of care guidelines is due to manpower limitation and difficulties in engaging with young and sometimes highly disabled children. Our group has been pioneering in developing the UK at-home individualised rehabilitation program. To address this challenge, the Investigators propose the development of an innovative, virtual targeted rehabilitation platform specifically designed for young patients with Spinal muscular atrophy. This technology aims to provide a patient-centric, at-home rehabilitation solution, enabling parents/caregivers to facilitate daily exercises in a more accessible and enjoyable manner. This technology would constitute the first of its kind in Spinal muscular atrophy field, involving the integration of augmented electromyography signals and soft robotic haptic devices into a gamified virtual reality environment. By increasing the frequency and quality of exercise interventions at home, this technology has the potential to significantly address the critical unmet need for consistent rehabilitation. This technology will also serve as a clinical outcome measure for continuous home-based assessments of weaker and less functional population in place of hospital-based assessments.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Cohort 1 Inclusion Criteria:
* Person with SMA
* A person living with genetically confirmed SMA aged from 12-18 years
* A good understanding of English or someone who can provide a good understanding of English for me to complete the survey
* A young person living with SMA from 12-15 years o…
Cohort 1 Inclusion Criteria:
* Person with SMA
* A person living with genetically confirmed SMA aged from 12-18 years
* A good understanding of English or someone who can provide a good understanding of English for me to complete the survey
* A young person living with SMA from 12-15 years of age and who's caregiver/legal guardian gives consent
* A young person living with SMA from 16-18 years of age who provide their own consent
Caregiver/ Legal Guardian
* A caregiver (legal guardian) of child/young person living with SMA aged from 6-18 years old
* A good understanding of English or someone who can provide a good understanding of English for me to complete the survey
Exclusion Criteria: No exclusion criteria for Cohort 1, other than meeting the inclusion criteria
Cohort 2 Inclusion Criteria:
Participant with SMA aged 6-10 years
* Genetically confirmed SMA
* A comprehensive understanding of English
* Treated with any disease-modifying therapy post-symptomatically
* Number of SMN2 copies available
* Functional status available
* Age: Participants between 6-10 years at Visit 1 (inclusion)
* Parent(s)/legal guardian(s)/caregiver(s) able to provide written informed consent and child able to provide assent prior to participation in the study
Participant with SMA aged 11-15 years
* Genetically confirmed SMA
* A comprehensive understanding of English
* Treated with any disease-modifying therapy post-symptomatically
* Number of SMN2 copies available
* Functional status available
* Age: Participants between 11-15 years at Visit 1 (inclusion)
* Parent(s)/legal guardian(s)/caregiver(s) able to provide written informed consent and child able to provide assent prior to participation in the study
Participant with SMA aged 16-18 years
* Genetically confirmed SMA
* A comprehensive understanding of English
* Treated with any disease-modifying therapy post-symptomatically
* Number of SMN2 copies available
* Functional status available
* Age: Participants between 16-18 years at Visit 1 (inclusion)
* Able to provide written informed consent
Exclusion Criteria:
Any acute or chronic condition which, according to the investigator, significantly interferes with the use of the device (example: Upper limbs injuries interfering with technology, skin conditions preventing the use of electrodes, etc)
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
